|Videos|September 6, 2016

How Do EDCs Interact with Larvae to Change Infected Mosquitoes?

Justin R. Anderson, PhD, associate professor of biology at Radford University, discusses how endocrine disrupting chemicals interact with larvae to change infected mosquitoes.

Justin R. Anderson, PhD, associate professor of biology at Radford University, discusses how endocrine disrupting chemicals (EDCs) interact with larvae to change infected mosquitoes.

Interview Transcript (slightly modified for readability)

“Endocrine disrupters are environmental contaminants, so [Bisphenol A] BPA for example, is a plasticizer that helps produce the plastics in environmental waste. If somebody throws out a water bottle, for example, and it contains water, that BPA can leach back out into the water. The mosquitoes that we’re interested in lay their eggs in containers, and so, as those larvae develop into adult mosquitoes, they’re going to be exposed to those EDCs in the water that they’re growing in.

We wanted to see what would happen to those mosquitoes; our findings show that we kill a significant number of those mosquitoes. The BPA or the BPS, Bisphenol S, or Butylated hydroxyanisole, BHA, which is a preservative, will kill developing mosquito larvae; somewhere between 100% for BHA down to about 40% of the mosquitoes will die. The ones that survive, we tested the females to see what happened in terms of their reproductive potential and for a couple of the endocrine disrupters, we actually saw an increase in the number of eggs that were laid. They lay more eggs if they survive, which sort of counterbalances the loss due to mortality.

We also saw that, depending on the concentration, depending on the endocrine disrupter that we used, we got changes to the size of the mosquitoes: some of them were bigger, some of them were smaller. We didn’t really notice any trends yet, but it turns out that depending on a virus and a mosquito, bigger mosquitoes may transmit the virus more, or in different systems, [while] the smaller mosquitoes will actually transmit the virus more. We haven’t really looked at a specific virus vector system yet, but we know that body size is an important predictor for [the question of wether] the mosquito [can] transmit the virus.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.